AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8200333 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (HF, 40.7 E%) during energy restriction
Number of subjects: 10
Study 8200333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (LF, 18.6 E%) during energy restriction
Number of subjects: 10
Study 8200333 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake increase during P3
Number of subjects: 10
Study 8200333 — intervention group
Group type: COMPARATOR
Intervention: Energy restriction
Number of subjects: 10
Study 3336984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol followed by oral metoprolol
Number of subjects: 20
Study 3336984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30695293 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/d
Number of subjects: 202
Study 30695293 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/d
Number of subjects: 202
Study 30695293 — intervention group
Group type: COMPARATOR
Intervention: Valbenazine 40 and/or 80 mg/d
Number of subjects: 202
Study 26940056 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher reports of anxiety during the initial consultation
Number of subjects: 2891
Study 26940056 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher reports of depression during the initial consultation
Number of subjects: 2891
Study 24381187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (intervention group)
Number of subjects: 126
Study 24381187 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 126
Study 23777561 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 74
Study 23777561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 20643425 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month behavioral weight loss intervention
Number of subjects: 338
Study 20643425 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 338
Study 18757465 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign brain tumors patients (n=5)
Number of subjects: 14
Study 18757465 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal sclerosis patients (n=9)
Number of subjects: 14
Study 18757465 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=14)
Number of subjects: 14
Study 15851642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography for detecting vertebral fractures
Number of subjects: 459
Study 15851642 — intervention group
Group type: COMPARATOR
Intervention: Official radiologists' reports
Number of subjects: 459
Study 15851642 — intervention group
Group type: EXPERIMENTAL
Intervention: History of osteoporosis
Number of subjects: 459
Study 15851642 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis medications
Number of subjects: 459
Study 12439707 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg m(‐2) every 3 weeks)
Number of subjects: 176
Study 12439707 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (750 mg m(‐2) per day continuous infusion D1-5) plus vinorelbine (25 mg m(‐2) D1 and D5 of each 3-week cycle
Number of subjects: 176
Study 10490748 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 33
Study 10490748 — intervention group
Group type: COMPARATOR
Intervention: Panoramic Radiography
Number of subjects: 33
Study 8604701 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA probands with hypertension and/or progressive renal impairment
Number of subjects: 0
Study 8604701 — intervention group
Group type: COMPARATOR
Intervention: First-degree relatives of patients with IgAN
Number of subjects: 0
Study 8604701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive relatives of IgAN patients
Number of subjects: 0
Study 8604701 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA probands and their first-degree relatives
Number of subjects: 0
Study 8604701 — intervention group
Group type: EXPERIMENTAL
Intervention: Na/Li CT kinetics
Number of subjects: 0
Study 2022561 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant DNA human GH (rhGH) 0.07 U/kg body wt daily for 6 months
Number of subjects: 24
Study 2022561 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 7225166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 400 mg/day
Number of subjects: 56
Study 7225166 — intervention group
Group type: COMPARATOR
Intervention: Clofibate 2 g/day
Number of subjects: 56
Study 31256093 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroDRIVE intervention
Number of subjects: 17
Study 31256093 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 17
Study 27836404 — intervention group
Group type: EXPERIMENTAL
Intervention: Octyl cyanoacrylate skin adhesive
Number of subjects: 109
Study 27836404 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 109
Study 25884724 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (two different daily doses)
Number of subjects: 0
Study 25884724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun exposure (two different patterns)
Number of subjects: 0
Study 25884724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23630052 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (65 mg · kg ‐ 1BM)
Number of subjects: 16
Study 23630052 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Number of subjects: 16
Study 23630052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose monohydrate)
Number of subjects: 16
Study 21366944 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR)
Number of subjects: 30
Study 19515873 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg), vitamin B(12) (400 microg), vitamin B(6) (10 mg) daily
Number of subjects: 240
Study 19515873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 15673860 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 4 mg IV
Number of subjects: 92
Study 15673860 — intervention group
Group type: EXPERIMENTAL
Intervention: dolasetron 12.5 mg IV
Number of subjects: 92
Study 15673860 — intervention group
Group type: EXPERIMENTAL
Intervention: dolasetron
Number of subjects: 92
Study 12629227 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash injury
Number of subjects: 181
Study 12629227 — intervention group
Group type: COMPARATOR
Intervention: Ankle injury
Number of subjects: 181
Study 10555719 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly retrospective written feedback mailed to residents detailing their missed immunization opportunities and appointment failure rates over a 12‐month period.
Number of subjects: 32
Study 10555719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 10555719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups with fewer than 2 visits during the second year of life
Number of subjects: 32
Study 10555719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups with 2 visits during the second year of life
Number of subjects: 32
Study 10555719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups with more than 2 visits during the second year of life
Number of subjects: 32
Study 8677278 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone phonophoresis (10% hydrocortisone acetate, ultrasound at 1.0 W/cm2 for 5 minutes)
Number of subjects: 16
Study 8677278 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (ultrasound alone)
Number of subjects: 16
Study 1925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled teacher model
Number of subjects: 100
Study 1925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Unskilled teacher model
Number of subjects: 100
Study 1925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled peer model
Number of subjects: 100
Study 1925046 — intervention group
Group type: EXPERIMENTAL
Intervention: Unskilled peer model
Number of subjects: 100
Study 1925046 — intervention group
Group type: COMPARATOR
Intervention: No model (control group)
Number of subjects: 100
Study 6315514 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre diet (51.4 g dietary fibre/24 h)
Number of subjects: 100
Study 6315514 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary advice (12.4 g dietary fibre/24 h)
Number of subjects: 100
Study 30625398 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 83
Study 30625398 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with adjunct antimicrobial photodynamic therapy (aPDT)
Number of subjects: 83
Study 28642208 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-enhanced cognitive behavioral group therapy (IE-CBGT)
Number of subjects: 96
Study 28642208 — intervention group
Group type: COMPARATOR
Intervention: Verbally-based cognitive behavioral group therapy (VB-CBGT)
Number of subjects: 96
Study 28642208 — intervention group
Group type: EXPERIMENTAL
Intervention: IE-CBGT
Number of subjects: 96
Study 25680595 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) with oxaliplatin 130 mg/m² on day 1 and S1 at 40 mg/m² twice daily on days 1‐14, followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m² on days 1 and 21 and S1 30 mg/m² twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A)
Number of subjects: 97
Study 25680595 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) followed by esophagectomy without ICT (arm B)
Number of subjects: 97
Study 25680595 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) with oxaliplatin and S1 (arm A)
Number of subjects: 97
Study 25680595 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) without ICT (arm B)
Number of subjects: 97
Study 23305613 — intervention group
Group type: EXPERIMENTAL
Intervention: King laryngeal tube (KLT) airway
Number of subjects: 67
Study 23305613 — intervention group
Group type: COMPARATOR
Intervention: Basic airway management (bag‐mask ventilation [BMV])
Number of subjects: 67
Study 21512258 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fondaparinux
Number of subjects: 80
Study 21512258 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin (UFH)
Number of subjects: 80
Study 19039051 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular decompression surgery
Number of subjects: 66
Study 19039051 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 66
Study 19039051 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected trigeminal nerve
Number of subjects: 66
Study 19039051 — intervention group
Group type: COMPARATOR
Intervention: Contralateral trigeminal nerve
Number of subjects: 66
Study 19039051 — intervention group
Group type: COMPARATOR
Intervention: Normal trigeminal nerves
Number of subjects: 66
Study 17711768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-guided surgical excision
Number of subjects: 51
Study 17711768 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision with surgeon‐delineated excision margins
Number of subjects: 51
Study 16013776 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC formulations containing rifampicin, isoniazid, and ethambutol hydrochloride
Number of subjects: 22
Study 12204509 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg and cobalamin 400 microg daily
Number of subjects: 15
Study 12204509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10476895 — intervention group
Group type: EXPERIMENTAL
Intervention: GBA group (polylactide bioabsorbable membrane, DFDBA plus antibiotics)
Number of subjects: 24
Study 10476895 — intervention group
Group type: COMPARATOR
Intervention: GB group (polylactide membrane and DFDBA alone)
Number of subjects: 24
Study 10476895 — intervention group
Group type: EXPERIMENTAL
Intervention: GBA group
Number of subjects: 24
Study 10476895 — intervention group
Group type: COMPARATOR
Intervention: GB group
Number of subjects: 24
Study 8945694 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeneck clinical staging system
Number of subjects: 335
Study 8945694 — intervention group
Group type: EXPERIMENTAL
Intervention: Royce clinical staging system
Number of subjects: 335
Study 8945694 — intervention group
Group type: COMPARATOR
Intervention: CD4 count
Number of subjects: 335
Study 1952442 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sleep fragmentation (arousal to an auditory stimulus after each minute of sleep)
Number of subjects: 13
Study 1952442 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 13
Study 6299752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (acute and chronic administration)
Number of subjects: 0
Study 6299752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (acute administration)
Number of subjects: 0
Study 6299752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 6299752 — intervention group
Group type: COMPARATOR
Intervention: Clonidine and Methyldopa
Number of subjects: 0
Study 31555441 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc treatment
Number of subjects: 13191
Study 30272851 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsule of Bifidobacterium longum and Lactobacillus acidophilus (2 × 10^7 CFU/day)
Number of subjects: 75
Study 30272851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (10 g/day inulin)
Number of subjects: 75
Study 30272851 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of probiotic and prebiotic
Number of subjects: 75
Study 30272851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 26386707 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy (methotrexate and celecoxib)
Number of subjects: 87
Study 26386707 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin chemotherapy
Number of subjects: 87
Study 24423407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue cleaning
Number of subjects: 30
Study 24423407 — intervention group
Group type: COMPARATOR
Intervention: No tongue cleaning (Control)
Number of subjects: 30
Study 22199016 — intervention group
Group type: EXPERIMENTAL
Intervention: New or recurrent myocardial infarction (MI)
Number of subjects: 13608
Study 22199016 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 4a MI (peri-percutaneous coronary intervention)
Number of subjects: 13608
Study 22199016 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 4b MI (stent thrombosis)
Number of subjects: 13608
Study 22199016 — intervention group
Group type: EXPERIMENTAL
Intervention: Any MI
Number of subjects: 13608
Study 20302615 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 300
Study 20302615 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Psycho‐Education (CPE)
Number of subjects: 300
Study 20302615 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 300
Study 17090640 — intervention group
Group type: EXPERIMENTAL
Intervention: MA/TE (Megestrol Acetate + Testosterone Enanthate)
Number of subjects: 79
Study 17090640 — intervention group
Group type: COMPARATOR
Intervention: MA/PL (Megestrol Acetate + Placebo)
Number of subjects: 79
Study 16303697 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements (1 mg/kg/d) from 4‐9 mo of age
Number of subjects: 214
Study 16303697 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements from 6‐9 mo
Number of subjects: 214
Study 16303697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 11991311 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine‐containing wax
Number of subjects: 14
Study 11991311 — intervention group
Group type: COMPARATOR
Intervention: Placebo wax
Number of subjects: 14
Study 9856716 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (2 mg) with lidocaine, 2% epidurally and lidocaine, 1% for local skin infiltration
Number of subjects: 1000
Study 9856716 — intervention group
Group type: COMPARATOR
Intervention: Control group received lidocaine, 2% epidurally and lidocaine, 1% for local skin infiltration
Number of subjects: 1000
Study 8669876 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of fibrin glue (Tissucol) applied to the wound cavity
Number of subjects: 40
Study 8669876 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 patients who underwent surgery without fibrin glue)
Number of subjects: 40
Study 2194314 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg twice daily
Number of subjects: 43
Study 2194314 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study 692548 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling as hypertensive
Number of subjects: 0
Study 692548 — intervention group
Group type: COMPARATOR
Intervention: General employee population
Number of subjects: 0
Study 692548 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of hypertension
Number of subjects: 0
Study 692548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low compliance with treatment
Number of subjects: 0
Study 29536820 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 54
Study 29536820 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 26426276 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-P ON
Number of subjects: 44
Study 26426276 — intervention group
Group type: COMPARATOR
Intervention: CRT-P OFF
Number of subjects: 44
Study 24103211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 22
Study 24103211 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (Control)
Number of subjects: 22
Study 22506692 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% tranexamic acid
Number of subjects: 23
Study 22506692 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 23
Study 20688744 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron 20 mg/d
Number of subjects: 25
Study 20688744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18494840 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session case management intervention
Number of subjects: 936
Study 18494840 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 936
Study 15925161 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolac nerve guide (Polyganics B.V.)
Number of subjects: 30
Study 15925161 — intervention group
Group type: COMPARATOR
Intervention: Standard reconstruction techniques
Number of subjects: 30
Study 12949718 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily for >14 days
Number of subjects: 44
Study 12949718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12949718 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 44
Study 10566707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg subcutaneous (s.c.)
Number of subjects: 13
Study 8678099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 1 g every 12 hours
Number of subjects: 336
Study 8678099 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 1 g every 8 hours
Number of subjects: 336
Study 8678099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (blinded study)
Number of subjects: 336
Study 8678099 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (blinded study)
Number of subjects: 336
Study 1985504 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 at 240 micrograms/kg
Number of subjects: 72
Study 1985504 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 at 300 micrograms/kg
Number of subjects: 72
Study 1985504 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 at 75 micrograms/kg
Number of subjects: 72
Study 1985504 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 at 100 micrograms/kg
Number of subjects: 72
Study 1985504 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 (up to 5 maintenance doses)
Number of subjects: 72
Study 1985504 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426 (doses used in the study)
Number of subjects: 72
Study 1985504 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9426
Number of subjects: 72
Study 6684719 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g every 8 hours for 5 to 10 days)
Number of subjects: 21
Study 6684719 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (1 g every 8 hours for 5 to 10 days)
Number of subjects: 21
Study 31469084 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based peer-support intervention program (PIP)
Number of subjects: 138
Study 31469084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus peer support
Number of subjects: 138
Study 31469084 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 138
Study 29858418 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture and placebo medicine
Number of subjects: 60
Study 29858418 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture and real medicine (topiramate)
Number of subjects: 60
Study 27277941 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based daycare program
Number of subjects: 3177
Study 23969994 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (two one-hour sessions a week for four weeks)
Number of subjects: 48
Study 23969994 — intervention group
Group type: COMPARATOR
Intervention: Cooking intervention (two one-hour sessions a week for four weeks)
Number of subjects: 48
Study 23969994 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 48
Study 23969994 — intervention group
Group type: COMPARATOR
Intervention: Cooking intervention
Number of subjects: 48
Study 22085203 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA density (PSAD) for Gleason score 6
Number of subjects: 1516
Study 22085203 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA density (PSAD) for Gleason score 3 + 4 = 7
Number of subjects: 1516